Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: Cancer Res. 2020 Mar 25;80(13):2848–2860. doi: 10.1158/0008-5472.CAN-19-3033

Figure 4. RNF168 delays BRCA1 mutant tumor formation.

Figure 4.

(A) Dox-inducible GFP (green lines) and RNF168 (red lines) MDA-MB-436 +/− BRCA1 cell lines were injected into mice and tumor sizes measured. Individual tumor volumes are displayed (n=5, minimum), including instances when injected cells did not form tumors

(B) Established tumors samples described in (A) were subjected to Western blotting for the indicated proteins. Two tumor samples were analyzed per group.

(C) BRCA1 mutant PDX124 and PDX056 were transduced with lentivirus to express GFP or GFP-tagged RNF168, sorted and injected into mice. Individual tumor volumes showing tumor growth are displayed (n=6 minimum), including include instances when injected cells did not form tumors. See Fig. S4E for more details.

(D) Established tumors from (C) were collected and compared with transduced cells that were generated prior to injection by Western blotting.